ÂÜŔňÂŇÂ×

Patricia Watson, VP Regulatory Affairs, has over 40 years of pharmaceutical regulatory affairs experience with a deep history of successful regulatory strategies and submissions. As part of Phlow’s™ founding team, she was drawn to the organization’s mission from the very beginning to ensure every human being has access to the essential medicines necessary to sustain life and conquer disease. Prior to Phlow™, Pat was the executive director of CMC Regulatory Affairs for Boehringer Ingelheim Pharmaceuticals, where she founded CMC regulatory affairs as a separate function within the company and led a staff whose regulatory responsibilities encompassed the entire product lifecycle: development, registration and post-approval maintenance. Pat has extensive knowledge of current and emerging U.S., EU and ICH CMC regulatory requirements for clinical trials, marketing authorization applications, and post-approval changes. She also has expertise with requirements for active pharmaceutical ingredients, and dosage forms including solid oral dosage forms and injections. In addition, Pat has been actively engaged in numerous PhRMA initiatives and working groups dealing with ICH and FDA guidelines and policy development. Pat earned a Bachelor of Science in Chemistry from University of Missouri and Master of Science in Biochemistry from New York Medical College.